Press Releases

Our news.

All Posts
Press Releases

KIFFIK Biomedical Establishes Strategic Partnership with Beacon MedTech Solutions to Commercialize its K-EXP™ Platform

April 16, 2026/

Clinical device expected availability in 2026 Scalable platform launch planned for 2027 [ MIAMI ] — KIFFIK Biomedical Inc. (“KIFFIK”), a leader in interstitial fluid (ISF)-based diagnostics, today announced a strategic manufacturing partnership with Beacon MedTech Solutions to deliver its K-EXP™ platform. The K-EXP™ clinical device is expected to be...

KIFFIK Biomedical and HekaBio Announce Strategic Alliance to Expand ISF-Based Molecular Access Across Asia-Pacific

March 24, 2026/

The K-EXP™ platform enables direct access to interstitial fluid for molecular measurement at the source Partnership supports regulatory, clinical, and commercial expansion across Japan and Asia-Pacific [ MIAMI, FL AND TOKYO, JAPAN / ACCESS Newswire ] – KIFFIK Biomedical today announced a strategic alliance with HekaBio K.K. to expand access...

KIFFIK Biomedical Onboards Industry Leaders Rene Veloso & Dr. Reginald Swift

August 13, 2025/

Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations. Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations. Rubix Life Sciences CEO Reginald Swift, Ph.D. joins as Chief Scientific Officer with responsibility...

Kiffik Biomedical & Rubix LS Partner To Revolutionize Cancer Diagnostics With Interstitial Fluid & Aptamer Technologies

March 20, 2025/

[Providence, RI, 03/20/2025] – Kiffik Biomedical, a leader in interstitial fluid (ISF)-based diagnostics, has announced a strategic partnership with Rubix LS, a pioneer in aptamer-based precision medicine, to develop a first-of-its-kind rapid colorectal cancer test. This collaboration combines KIFFIK’s groundbreaking ISF biomarker collection technology with Rubix LS’s advanced aptamer detection...

Global Partnership with Duracell Batteries to Power New, Innovative Health Monitoring Technology

February 19, 2025/

Duracell® batteries will be integrated into KIFFIK Biomonitoring Devices, such as health monitors, that detect various biomarkers in the body. [Providence, RI, 01/29/2025] – KIFFIK Biomedical and Duracell U.S. Operations, Inc. (“Duracell”) have agreed to collaborate and assess the integration of long-lasting, efficient power solutions with cutting-edge biomonitoring technology. This...

Dermatology: Non-invasive assessment of skin inflammation, disease flares (e.g., eczema, psoriasis), and potentially early indicators of melanoma or other skin cancers

Beauty & Wellness: Real-time monitoring of skin barrier integrity, hydration, oxidative stress, and treatment response for personalized skincare routines

Our news.

KIFFIK Biomedical Establishes Strategic Partnership with Beacon MedTech Solutions to Commercialize its K-EXP™ Platform

KIFFIK Biomedical and HekaBio Announce Strategic Alliance to Expand ISF-Based Molecular Access Across Asia-Pacific

KIFFIK Biomedical Onboards Industry Leaders Rene Veloso & Dr. Reginald Swift

Kiffik Biomedical & Rubix LS Partner To Revolutionize Cancer Diagnostics With Interstitial Fluid & Aptamer Technologies

Global Partnership with Duracell Batteries to Power New, Innovative Health Monitoring Technology

Navigation

FOLLOW US

The challenge.

The opportunity.

Clinical application:

Potential biomarkers:

Estradiol (E2)

Luteinizing Hormone (LH)

Progesterone

Follicle-Stimulating Hormone (FSH)

Anti-Müllerian Hormone (AMH)

Hormonal health shouldn’t be a guessing game. With KIFFIK, women can see their cycle, and their care, more clearly than ever before.

The challenge.

The opportunity.

Clinical application:

Potential biomarkers:

Interleukin-6 (IL-6)

S100B (neurotrauma indicator)

Lactate (tissue hypoxia)

D-dimer (coagulation dysfunction)

Myoglobin (muscle damage)

TNF-α (systemic inflammation)

When every second counts, insight can’t wait for the hospital. KIFFIK’s platform is designed to move with the mission — delivering data where it’s needed most.

The challenge.

The opportunity.

Clinical application:

Potential biomarkers:

Prostate-Specific Antigen (PSA)

PCA3 (Prostate Cancer Antigen 3)

Alpha-methylacyl-CoA racemase (AMACR)

Circulating tumor DNA (ctDNA) for mutation profiling

Interleukin-8 (IL-8) and other inflammation markers

Continuous insight without constant disruption, KIFFIK’s platform enables smarter, patient-centered care for prostate cancer across the spectrum of disease.

The challenge.

The opportunity.

Clinical application:

Potential biomarkers:

IL-6, CRP (inflammatory signaling)

Adiponectin, leptin (metabolic regulation)

VEGF, IL-8 (oncogenic pathways)

S100B, GFAP (neuroinflammatory injury)

Every breakthrough begins with better data. KIFFIK gives researchers a new lens on human biology, continuously, painlessly, and in real time.

The challenge.

The opportunity.

Clinical application:

Potential biomarkers:

Procalcitonin (PCT)

C-reactive protein (CRP)

Interleukin-6 (IL-6)

TNF-α (Tumor Necrosis Factor-alpha)

Lactate

When sepsis moves fast, we have to move faster. KIFFIK’s platform could help detect the warning signs before symptoms spiral.

The challenge.

The opportunity.

Clinical application:

Potential biomarkers:

Interleukin-1α (IL-1α)

Interleukin-8 (IL-8)

TNF-α

MMP-9 (Matrix metalloproteinase-9)

Reactive oxygen species (ROS)

Natural moisturizing factor (NMF) markers

The skin is always speaking — through irritation, inflammation, and subtle shifts. With ISF, we can finally hear it clearly, and respond in real time.

The challenge.

The opportunity.

Clinical application:

Potential biomarkers:

GFAP (Glial Fibrillary Acidic Protein)

UCH-L1 (Ubiquitin C-terminal hydrolase L1)

S100B

Interleukin-6 (IL-6)

Tau protein fragments

Early detection of brain injury doesn't have to wait for imaging. With ISF, it could happen in minutes — where it matters most.

The challenge.